Correlation Between Access Blood Flow and Extracorporeal Blood Flow

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00522704

Enrollment

Registered

2007-08-30

Start date

2008-03-31

Completion date

2015-06-30

Last updated

2014-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriovenous Fistula

Keywords

Arteriovenous fistula, Access blood flow, Extracorporeal blood flow, Dynamic arterial line pressure, Hemodialysis treatment

Brief summary

The purpose of this study is to determine if Effective Extracorporeal Blood Flow(eEBF) has correlation with Access Blood Flow (Qa), when eEBF adjusts with Dynamic Arterial Line Pressure (DALP) in patients with Arteriovenous fistulae in hemodialysis treatment.

Detailed description

Accesses that show a large (\>15%) decrement over time in vascular access blood flow are associated with a high risk of thrombosis. Serial measurements of vascular access blood flow predict access thrombosis. At the moment, the measurement of access flow is time consuming, operator dependent, so that it cannot be done with every treatment. We hypothesized that extracorporeal blood flow at pressure of -200 to -260 mmHg in arterial line has correlation with access blood flow and this can be used to estimate access blood flow.

Interventions

OTHERDynamic Arterial line Pressure (DALP)

eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with Chronic Kidney Disease K-DIGO 5d in hemodialysis treatment) * Permanent vascular accesses with native arteriovenous fistulas (AVF) * AVF that were at least 12 weeks old

Exclusion criteria

* Inflammation and pain in AVF * Negation to participate in the study

Design outcomes

Primary

Measure	Time frame	Description
Acces Blood Flow	Acces Blood Flow	Acces Blood Flow: cuantity of Blood that Flow throw venous acces in ml/min

Countries

Mexico

Contacts

Primary ContactFranklin B Mora, M.D.

franklin.mora.bravo@gmail.com593 72 868084

Backup ContactLuis R Mariscal, M.D.

mariscalmd@yahoo.com.mx52 55 55 7932911

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026